ARCHIVES

Ibrutinib Increases OS, PFS Versus Ofatumumab in Phase III

This article is from The Cancer Letter archive.

Vol. 37 No. 6 | June 27, 2014

Download PDF Visit The Full Archive

Related Articles

Obama Administration, WellPoint, Face Off Over Allegation Of Coverage Recissions

April 30, 2010

Reports On Nutrition & Cancer Show Needs For More Clinical Studies

September 5, 1975

Biotheraputics Inc. Markets ‘Custom Made’ Experimental Therapy

August 9, 1985

In Brief: HHS Names Deputy HCFA Administrator; M.D. Anderson’s Error-Free Record Honored

July 4, 1997

Scrutiny of caBIG Exposes Conflicts, Bonanza For Contractors

March 18, 2011

Research Training – On The Road Back, With Trainee Stipends, Payback Feature

June 14, 1974